Skip to content
Catalyst

crocin-1What was measured

Measured, with no finding

104 endpoints

Show what was measuredHide what was measured
  • Beck Anxiety Inventory score

    decreases, b -4.35; 95% CI -5.94, -2.75

    Not recorded as a finding: No node for Beck Anxiety Inventory (the listed anxiety nodes are HAM-A and a pooled composite).

    After 8-week intervention, crocin significantly decreased Beck Depression Inventory (b - 6.66; 95% CI, - 9.88, - 3.45; P < 0.0001), Beck Anxiety Inventory (b - 4.35; 95% CI, - 5.94, - 2.75; P < 0.0001), general health questionnaire (b - 4.45; 95% CI, - 7.68, - 1.22; P = 0.008) and Pittsburgh Sleep Quality Index (b - 2.73; 95% CI, - 3.74, - 1.73; P < 0.0001) in patients under MMT, compared with the placebo.

    PMID 30795785 · both readings recorded this

  • Beck Anxiety Inventory

    decreases, p = 0.0001

    Beck Anxiety Inventory (b - 4.35; 95% CI, - 5.94, - 2.75; P < 0.0001)

    PMID 30795785 · one of two readings recorded this

  • Beck Depression Inventory

    decreases, p = 0.0001

    crocin significantly decreased Beck Depression Inventory (b - 6.66; 95% CI, - 9.88, - 3.45; P < 0.0001)

    PMID 30795785 · one of two readings recorded this

  • General Health Questionnaire score

    decreases, b -4.45; 95% CI -7.68, -1.22, p = 0.008

    Not recorded as a finding: No node for the General Health Questionnaire.

    After 8-week intervention, crocin significantly decreased Beck Depression Inventory (b - 6.66; 95% CI, - 9.88, - 3.45; P < 0.0001), Beck Anxiety Inventory (b - 4.35; 95% CI, - 5.94, - 2.75; P < 0.0001), general health questionnaire (b - 4.45; 95% CI, - 7.68, - 1.22; P = 0.008) and Pittsburgh Sleep Quality Index (b - 2.73; 95% CI, - 3.74, - 1.73; P < 0.0001) in patients under MMT, compared with the placebo.

    PMID 30795785 · both readings recorded this

  • General health questionnaire

    decreases, p = 0.008

    general health questionnaire (b - 4.45; 95% CI, - 7.68, - 1.22; P = 0.008)

    PMID 30795785 · one of two readings recorded this

  • International Index of Erectile Function score

    increases, b 4.98; 95% CI 2.08, 7.88, p = 0.001

    Not recorded as a finding: No node for the International Index of Erectile Function (the listed sexual-function nodes are FSFI and a pooled composite).

    Crocin also significantly improved International Index of Erectile Functions (b 4.98; 95% CI, 2.08, 7.88; P = 0.001) rather than placebo.

    PMID 30795785 · both readings recorded this

  • International Index of Erectile Function

    increases, p = 0.001

    Crocin also significantly improved International Index of Erectile Functions (b 4.98; 95% CI, 2.08, 7.88; P = 0.001)

    PMID 30795785 · one of two readings recorded this

  • Pittsburgh Sleep Quality Index

    decreases, p = 0.0001

    Pittsburgh Sleep Quality Index (b - 2.73; 95% CI, - 3.74, - 1.73; P < 0.0001)

    PMID 30795785 · one of two readings recorded this

  • Total cholesterol (TC)

    decreases

    TC levels in the saffron group were 0.19 lower and 0.11 fold lower in crocin group than in the placebo group

    PMID 32013614 · one of two readings recorded this

  • Total cholesterol (TC)

    decreases

    TC levels in the saffron group were 0.19 lower and 0.11 fold lower in crocin group than in the placebo group

    PMID 32013614 · one of two readings recorded this

  • Blood glucose

    no effect

    The blood glucose levels did not significantly differ from the control group

    PMID 32013614 · one of two readings recorded this

  • HDL-C, LDL-C, total cholesterol, triglycerides and blood glucose, saffron and crocin pooled versus placebo

    increases, HDL-C 0.01 fold higher in the crocin group than placebo

    Not recorded as a finding: no estimate is reported anywhere

    A pooled analysis using a model for random-effects showed that HDL-C levels were 0.21 fold higher in the saffron and 0.01 fold higher in the crocin group than placebo.

    PMID 32013614 · one of two readings recorded this

  • HDL-C

    increases

    HDL-C levels were 0.21 fold higher in the saffron and 0.01 fold higher in the crocin group than placebo

    PMID 32013614 · one of two readings recorded this

  • HDL-C

    increases

    HDL-C levels were 0.21 fold higher in the saffron and 0.01 fold higher in the crocin group than placebo

    PMID 32013614 · one of two readings recorded this

  • LDL-C

    decreases

    LDL-C levels in the saffron group reduced by 0.51 and 0.04 fold in the crocin group versus the placebo

    PMID 32013614 · one of two readings recorded this

  • LDL-C

    decreases

    LDL-C levels in the saffron group reduced by 0.51 and 0.04 fold in the crocin group versus the placebo

    PMID 32013614 · one of two readings recorded this

  • serum HDL-C, LDL-C, total cholesterol and TG, pooled fold-differences for saffron and crocin groups versus placebo

    HDL-C 0.01 fold higher in the crocin group than placebo

    Not recorded as a finding: a direction is stated and the estimate does not support it

    A pooled analysis using a model for random-effects showed that HDL-C levels were 0.21 fold higher in the saffron and 0.01 fold higher in the crocin group than placebo.

    PMID 32013614 · one of two readings recorded this

  • Triglycerides (TG)

    decreases

    TG level in saffron group was 0.04 lower and 0.02 fold lower in crocin than the control group

    PMID 32013614 · one of two readings recorded this

  • Triglycerides (TG)

    decreases

    TG level in saffron group was 0.04 lower and 0.02 fold lower in crocin than the control group

    PMID 32013614 · one of two readings recorded this

  • Total cholesterol (TC)

    decreases, p = 0.01

    TC (WMD: -4.64 mg/l, 95 % CI, -8.19, -1.09; p = 0.010)

    PMID 32951748 · one of two readings recorded this

  • Fasting blood glucose (FBG) change versus intervention duration (meta-regression)

    modulates, p = 0.019

    Meta-regression analysis indicated a linear relationship between the duration of intervention and significant change in FBG (p = 0.019)

    PMID 32951748 · one of two readings recorded this

  • Fasting blood glucose (FBG)

    decreases, p = 0.019

    FBG (WMD: -6.52 mg/l, 95 % CI, -11.96, -1.08; p = 0.019)

    PMID 32951748 · one of two readings recorded this

  • Fasting blood glucose (FBG)

    no effect

    crocin supplementation did not significantly change FBG in trials that used low dose intervention

    PMID 32951748 · one of two readings recorded this

  • HDL-C

    no effect, p = 0.872

    Crocin supplements did not have any significant effect on serum TG (p = 0.144) levels, LDL-C (p = 0.161), and HDL-C (p = 0.872) levels

    PMID 32951748 · one of two readings recorded this

  • LDL-C

    no effect, p = 0.161

    Crocin supplements did not have any significant effect on serum TG (p = 0.144) levels, LDL-C (p = 0.161), and HDL-C (p = 0.872) levels

    PMID 32951748 · one of two readings recorded this

  • LDL-C

    decreases

    LDL-C levels in trials that used high dose intervention and trials that conducted on subjects with metabolic disorders

    PMID 32951748 · one of two readings recorded this

  • Serum triglycerides (TG)

    no effect, p = 0.144

    Crocin supplements did not have any significant effect on serum TG (p = 0.144) levels, LDL-C (p = 0.161), and HDL-C (p = 0.872) levels

    PMID 32951748 · one of two readings recorded this

  • Triglycerides (TG)

    decreases

    crocin supplementation could beneficially have effect on TG level only when trial duration less than 12 weeks

    PMID 32951748 · one of two readings recorded this

  • Blood urea nitrogen (BUN)

    no effect, p = 0.9, n = 40

    BUN (mg/dL) | 47.32 ± 27.83 | 46.65 ± 22.79 | −0.67 ± 16.79 | 0.86 | 45.06 ± 12.34 | 43.78 ± 13.01 | −1.28 ± 10.78 | 0.62 | 0.90

    PMID 36209091 · one of two readings recorded this

  • BMI, SBP, DBP (mercury sphygmomanometer, seated) and serum TGF-beta (ELISA) between-group change

    decreased in crocin group versus placebo, none statistically significant

    Not recorded as a finding: Direction word ('decreased') with a statement of non-significance but no estimate; one-sided, so no_effect is not supportable (direction_stated_but_not_significant).

    Moreover, the mean BMI, SBP, and DBP and median serum TGF-β levels decreased in the crocin group compared with the placebo group but none of these changes were statistically significant.

    PMID 36209091 · one of two readings recorded this

  • Body mass index (BMI)

    no effect, p = 0.3, n = 40

    BMI (kg/m2) | 27.21 ± 3.86 | 27.02 ± 3.95 | −0.46 ± 1.25 | 0.12 | 27.26 ± 3.34 | 27.16 ± 3.44 | −0.10 ± 0.56 | 0.49 | 0.30

    PMID 36209091 · one of two readings recorded this

  • C-reactive protein (CRP)

    no effect, p = 0.94, n = 40

    CRP (mg/dL) | 5.00 ± 0.50 | 5.00 ± 1.00 | 0.00 ± 1.50 | 0.79 | 5.00 ± 0.00 | 5.00 ± 0.00 | 0.00 ± 0.00 | 0.46 | 0.94

    PMID 36209091 · one of two readings recorded this

  • Diastolic blood pressure (DBP)

    no effect, p = 0.16, n = 40

    DBP (mm Hg) | 81.44 ± 16.46 | 77.19 ± 9.66 | −4.25 ± 17.02 | 0.33 | 75.33 ± 12.31 | 78.13 ± 8.87 | −2.80 ± 8.39 | 0.22 | 0.16

    PMID 36209091 · one of two readings recorded this

  • Erythrocyte sedimentation rate (ESR)

    no effect, p = 0.15, n = 40

    ESR (mm/hr) | 17.00 ± 28.00 | 22.00 ± 11.00 | 1.00 ± 15.50 | 0.98 | 17.50 ± 18.00 | 14.50 ± 17.00 | −2.50 ± 7.75 | 0.05 | 0.15

    PMID 36209091 · one of two readings recorded this

  • Estimated glomerular filtration rate (eGFR)

    no effect, p = 0.47, n = 40

    eGFR (mL/min/1.73 m2) | 61.00 ± 20.00 | 67.00 ± 36.00 | 0.00 ± 22.50 | 0.13 | 58.00 ± 39.25 | 62.00 ± 44.75 | 0.00 ± 9.75 | 0.94 | 0.47

    PMID 36209091 · one of two readings recorded this

  • fasting blood sugar and HbA1c (HPLC) change

    increased in both groups, greater in placebo, not significant

    Not recorded as a finding: Sentence names neither compound nor arm; increase in both groups, greater in placebo, not significant.

    Although this increase was greater in the placebo group, these changes were not significant.

    PMID 36209091 · one of two readings recorded this

  • Fasting blood sugar (FBS)

    no effect, p = 0.26, n = 40

    FBS (mg/dL) | 140.52 ± 36.71 | 146.24 ± 49.62 | 5.71 ± 38.58 | 0.51 | 136.58 ± 57.17 | 159.21 ± 62.62 | 22.63 ± 54.04 | 0.08 | 0.26

    PMID 36209091 · one of two readings recorded this

  • Glycated hemoglobin (HbA1c)

    no effect, p = 0.31, n = 40

    HbA1c (%) | 6.87 ± 0.67 | 7.03 ± 0.83 | 0.16 ± 0.56 | 0.22 | 7.32 ± 1.04 | 7.87 ± 1.69 | 0.48 ± 0.98 | 0.05 | 0.31

    PMID 36209091 · one of two readings recorded this

  • serum creatinine (Jaffe), eGFR (4-variable MDRD), CRP, ESR (Westergren), TC, HDL-C, LDL-C, BUN between-group changes

    no effect, changes not significantly different between the two groups

    Not recorded as a finding: Agentless sentence that names neither compound nor arm, so it does not support a claim on its own (quote_not_self_supporting).

    Mean values for changes in TC, HDL, LDL, BUN, and as well as median values for changes in SCr, ESR, CRP, urine microalbumin, uACR, and eGFR were not significantly different between the two groups.

    PMID 36209091 · one of two readings recorded this

  • Serum creatinine (SCr)

    no effect, p = 0.59, n = 40

    SCr (mg/dL) | 1.20 ± 0.40 | 1.10 ± 0.50 | 0.00 ± 0.30 | 0.41 | 1.10 ± 0.40 | 1.10 ± 0.70 | 0.00 ± 0.22 | 0.75 | 0.59

    PMID 36209091 · one of two readings recorded this

  • Serum HDL-C

    no effect, p = 0.84, n = 40

    Serum HDL-C (mg/dL) | 41.62 ± 9.93 | 45.95 ± 12.28 | 4.33 ± 14.36 | 0.18 | 48.68 ± 14.61 | 52.05 ± 14.41 | 3.37 ± 15.57 | 0.36 | 0.84

    PMID 36209091 · one of two readings recorded this

  • Serum LDL-C

    no effect, p = 0.43, n = 40

    Serum LDL-C (mg/dL) | 64.51 ± 23.44 | 63.95 ± 33.57 | −0.56 ± 26.58 | 0.92 | 79.21 ± 53.38 | 71.89 ± 61.40 | − 7.32 ± 26.41 | 0.24 | 0.43

    PMID 36209091 · one of two readings recorded this

  • Serum TGF-β

    no effect, p = 0.21, n = 40

    Serum TGF-β (ng/mL) | 17.10 ± 0.80 | 16.92 ± 0.85 | −0.21 ± 1.21 | 0.56 | 16.93 ± 1.98 | 17.29 ± 0.94 | 0.33 ± 2.40 | 0.35 | 0.21

    PMID 36209091 · one of two readings recorded this

  • Serum total cholesterol (TC)

    no effect, p = 0.26, n = 40

    Serum TC (mg/dL) | 133.24 ± 29.49 | 141.81 ± 40.97 | 8.57 ± 33.22 | 0.25 | 157.89 ± 58.85 | 156.21 ± 64.61 | −1.68 ± 22.33 | 0.75 | 0.26

    PMID 36209091 · one of two readings recorded this

  • Serum triglycerides (TG)

    decreases, p = 0.03, n = 40

    Serum TG (mg/dL) | 157.89 ± 84.69 | 133.79 ± 43.21 | −24.10 ± 74.57 | 0.17 | 143.52 ± 63.89 | 169.33 ± 69.71 | 25.81 ± 61.48 | 0.06 | 0.03*

    PMID 36209091 · one of two readings recorded this

  • Systolic blood pressure (SBP)

    no effect, p = 0.34, n = 40

    SBP (mm Hg) | 150.25 ± 18.08 | 143.13 ± 26.07 | −7.12 ± 14.95 | 0.07 | 138.20 ± 42.45 | 141.13 ± 18.71 | 2.93 ± 38.35 | 0.77 | 0.34

    PMID 36209091 · one of two readings recorded this

  • urine albumin-to-creatinine ratio (uACR), primary endpoint; serum creatinine (Jaffe), eGFR (MDRD), CRP, ESR, TC, HDL-C, LDL-C, BUN

    no effect, changes not significantly different between the two groups

    Not recorded as a finding: The only sentence reporting these does not name the compound (agentless, 'the two groups'); uACR also has no outcome node.

    Mean values for changes in TC, HDL, LDL, BUN, and as well as median values for changes in SCr, ESR, CRP, urine microalbumin, uACR, and eGFR were not significantly different between the two groups.

    PMID 36209091 · one of two readings recorded this

  • urine albumin-to-creatinine ratio (uACR), primary outcome, spot morning urine

    no effect, median changes in uACR not significantly different between the two groups

    Not recorded as a finding: No node: the listed urinary albumin excretion node requires a timed collection in ug/min, not a spot-urine ratio. Sentence is agentless and names no arm.

    Mean values for changes in TC, HDL, LDL, BUN, and as well as median values for changes in SCr, ESR, CRP, urine microalbumin, uACR, and eGFR were not significantly different between the two groups.

    PMID 36209091 · one of two readings recorded this

  • Urine albumin-to-creatinine ratio (uACR)

    no effect, p = 0.98, n = 40

    UACR (mg/g) | 161.00 ± 250.8 | 152.5 ± 188.8 | 10.5 ± 151 | 0.46 | 186.85 ± 240.8 | 157.5 ± 243.8 | 16 ± 143 | 0.58 | 0.98

    PMID 36209091 · one of two readings recorded this

  • Urine microalbumin

    no effect, p = 0.718, n = 40

    Urine micro albumin (mg/dL) | 185.0 ± 232.5 | 128.5 ± 287.4 | 34 ± 141.55 | 0.26 | 181.00 ± 316.80 | 141.00 ± 131.3 | 11.50 ± 248.75 | 0.98 | 0.718

    PMID 36209091 · one of two readings recorded this

  • Creatinine

    increases

    increased creatinine levels (WMD 0.24, 95%CI 0.17, 0.32)

    PMID 37778521 · one of two readings recorded this

  • Creatinine

    decreases

    creatinine (WMD -0.12, 95%CI -0.19, -0.05)

    PMID 37778521 · one of two readings recorded this

  • Aspartate aminotransferase (AST)

    decreases

    Saffron powdered plant decreased AST (WMD -1.19, 95%CI -2.24, -0.13)

    PMID 37778521 · one of two readings recorded this

  • Body mass index (BMI)

    increases

    increased BMI (WMD 0.56, 95%CI 0.07, 1.05)

    PMID 37778521 · one of two readings recorded this

  • Fasting blood glucose (FBG)

    decreases

    FBG (WMD -14.10, 95%CI -22.91, -5.30)

    PMID 37778521 · one of two readings recorded this

  • Fasting blood glucose (FBG)

    decreases

    FBG (WMD -26.90, 95%CI -38.87, -14.93)

    PMID 37778521 · one of two readings recorded this

  • Glycated hemoglobin (HbA1c)

    decreases

    crocin decreased HbA1c (WMD -0.43, 95%CI -0.66, -0.20)

    PMID 37778521 · one of two readings recorded this

  • Glycated hemoglobin (HbA1c)

    decreases

    saffron extract decreased HbA1c (WMD -0.35, 95%CI -0.65, -0.06)

    PMID 37778521 · one of two readings recorded this

  • HbA1c, fasting blood glucose (FBG), systolic blood pressure and creatinine in type 2 diabetes, pooled as before-after mean differences

    decreases, crocin HbA1c WMD -0.43 (95%CI -0.66, -0.20); FBG WMD -14.10 (95%CI -22.91, -5.30)

    Not recorded as a finding: the result compares a group with itself, not with a control

    Saffron powdered plant decreased AST (WMD -1.19, 95%CI -2.24, -0.13), but increased BMI (WMD 0.56, 95%CI 0.07, 1.05); saffron extract decreased HbA1c (WMD -0.35, 95%CI -0.65, -0.06), FBG (WMD -26.90, 95%CI -38.87, -14.93), creatinine (WMD -0.12, 95%CI -0.19, -0.05), and total cholesterol (WMD -9.29, 95%CI -18.25, -0.33); and crocin decreased HbA1c (WMD -0.43, 95%CI -0.66, -0.20), FBG (WMD -14.10, 95%CI -22.91, -5.30), and systolic blood pressure (WMD -8.18, 95%CI -12.75, -3.61), but increased creatinine levels (WMD 0.24, 95%CI 0.17, 0.32).

    PMID 37778521 · one of two readings recorded this

  • HbA1c, fasting blood glucose (FBG), systolic blood pressure and creatinine in type-2 diabetes, weighted mean differences (before-after)

    decreases, crocin: HbA1c WMD -0.43; FBG WMD -14.10; systolic blood pressure WMD -8.18; creatinine WMD 0.24

    Not recorded as a finding: the result compares a group with itself, not with a control

    Saffron powdered plant decreased AST (WMD -1.19, 95%CI -2.24, -0.13), but increased BMI (WMD 0.56, 95%CI 0.07, 1.05); saffron extract decreased HbA1c (WMD -0.35, 95%CI -0.65, -0.06), FBG (WMD -26.90, 95%CI -38.87, -14.93), creatinine (WMD -0.12, 95%CI -0.19, -0.05), and total cholesterol (WMD -9.29, 95%CI -18.25, -0.33); and crocin decreased HbA1c (WMD -0.43, 95%CI -0.66, -0.20), FBG (WMD -14.10, 95%CI -22.91, -5.30), and systolic blood pressure (WMD -8.18, 95%CI -12.75, -3.61), but increased creatinine levels (WMD 0.24, 95%CI 0.17, 0.32).

    PMID 37778521 · one of two readings recorded this

  • Systolic blood pressure

    decreases

    systolic blood pressure (WMD -8.18, 95%CI -12.75, -3.61)

    PMID 37778521 · one of two readings recorded this

  • Total cholesterol

    decreases

    total cholesterol (WMD -9.29, 95%CI -18.25, -0.33)

    PMID 37778521 · one of two readings recorded this

  • Change in total antioxidant capacity (TAC)

    increases, p = 0.01

    The mean ± SD of TAC change was 0.03 ± 0.07 mM vs. - 0.03 ± 0.09 mM in intervention and placebo groups, respectively (Time × group effect P: 0.01; effect size: 0.10)

    PMID 37917350 · one of two readings recorded this

  • CVLT-II-delay

    increases, p = 0.01

    CVLT-II-delay (P < 0.01; effect size: 0.29)

    PMID 37917350 · one of two readings recorded this

  • CVLT-II

    increases, p = 0.01

    The time effect of intervention on the California Verbal Learning Test second edition (CVLT-II) (P < 0.01; effect size: 0.29)

    PMID 37917350 · one of two readings recorded this

  • Glutathione reductase (GR) activity

    decreases, p = 0.01

    the time effect of intervention on GR activity was significant and decreasing in both groups (P < 0.01; effect size: 0.20)

    PMID 37917350 · one of two readings recorded this

  • serum total antioxidant capacity (colorimetric kit) in multiple sclerosis patients after 12 weeks of crocin-selenium nanoparticles versus placebo

    TAC change 0.03 +/- 0.07 mM versus -0.03 +/- 0.09 mM, time x group effect P 0.01, effect size 0.10, p = 0.01

    Not recorded as a finding: the intervention held more than the compound

    The mean ± SD of TAC change was 0.03 ± 0.07 mM vs. - 0.03 ± 0.09 mM in intervention and placebo groups, respectively (Time × group effect P: 0.01; effect size: 0.10).

    PMID 37917350 · one of two readings recorded this

  • Symbol Digit Modalities Test (SDMT)

    increases, p = 0.01

    the Symbol Digit Modalities Test (SDMT) (P < 0.01; effect size: 0.18)

    PMID 37917350 · one of two readings recorded this

  • total antioxidant capacity (colorimetric kit), glutathione reductase activity, malondialdehyde and BICAMS cognition in multiple sclerosis

    TAC change 0.03 ± 0.07 mM versus -0.03 ± 0.09 mM, intervention versus placebo, p = 0.01

    Not recorded as a finding: the intervention held more than the compound

    The mean ± SD of TAC change was 0.03 ± 0.07 mM vs. - 0.03 ± 0.09 mM in intervention and placebo groups, respectively (Time × group effect P: 0.01; effect size: 0.10).

    PMID 37917350 · one of two readings recorded this

  • HOMA-IR

    decreases, p = 0.002

    β - 0.18; 95% CI, - 0.29, - 0.07; P = 0.002

    PMID 38294505 · one of two readings recorded this

  • Anxiety

    no effect, p = 0.05

    nicotine dependence, depression, and anxiety inventory did not have a significant difference among the intervention groups (P > 0.05)

    PMID 38294505 · one of two readings recorded this

  • Depression

    no effect, p = 0.05

    nicotine dependence, depression, and anxiety inventory did not have a significant difference among the intervention groups (P > 0.05)

    PMID 38294505 · one of two readings recorded this

  • fasting plasma glucose (FPG), insulin, HOMA-IR and serum hs-CRP in smokers after 3 months of 30 mg/day crocin versus placebo

    FPG beta -3.27 mg/dL (95% CI -5.23, -1.31), p = 0.002

    Not recorded as a finding: the direction is carried only as a signed number

    Also in the secondary outcomes, fasting plasma glucose (FPG), insulin, and homeostasis model of assessment-insulin resistance (HOMA-IR) levels did indicate a significant difference by Cro intervention (β - 3.27 mg/dL; 95% CI, - 5.23, - 1.31; P = 0.002; β - 0.76 μIU/mL; 95% CI, - 1.38, - 0.15; P = 0.01; β - 0.18; 95% CI, - 0.29, - 0.07; P = 0.002), respectively.

    PMID 38294505 · one of two readings recorded this

  • Fasting plasma glucose

    decreases, p = 0.002

    β - 3.27 mg/dL; 95% CI, - 5.23, - 1.31; P = 0.002

    PMID 38294505 · one of two readings recorded this

  • hs-CRP

    decreases, p = 0.03

    hs-CRP) (β - 0.72 mg/L; 95% CI, - 1.37, - 0.07; P = 0.03)

    PMID 38294505 · one of two readings recorded this

  • Insulin

    decreases, p = 0.01

    β - 0.76 μIU/mL; 95% CI, - 1.38, - 0.15; P = 0.01

    PMID 38294505 · one of two readings recorded this

  • Nicotine dependence

    no effect, p = 0.05

    nicotine dependence, depression, and anxiety inventory did not have a significant difference among the intervention groups (P > 0.05)

    PMID 38294505 · one of two readings recorded this

  • serum high-sensitivity C-reactive protein, fasting plasma glucose, insulin and HOMA-IR in smokers after 3 months of crocin 30 mg/day versus placebo (Avicel)

    decreases, hs-CRP beta -0.72 mg/L; 95% CI -1.37, -0.07, p = 0.03

    Not recorded as a finding: the supporting sentence never names the compound

    There were also significant reductions in serum levels of high-sensitivity C-reactive protein (hs-CRP) (β - 0.72 mg/L; 95% CI, - 1.37, - 0.07; P = 0.03), compared with the placebo.

    PMID 38294505 · one of two readings recorded this

  • Anxiety (Beck anxiety scale)

    decreases, p = 0.01

    within-group comparisons showed crocin significantly decreased anxiety (p-value= 0.01)

    PMID 38306888 · one of two readings recorded this

  • anxiety on the Beck anxiety questionnaire

    decreases, within-group decrease, p = 0.01

    Not recorded as a finding: No outcome node for Beck Anxiety Inventory, and the reported result is a within-group comparison.

    In addition, within-group comparisons showed crocin significantly decreased anxiety (p-value= 0.01).

    PMID 38306888 · one of two readings recorded this

  • Beck anxiety questionnaire score, within-group comparison

    decreases, within-group decrease in anxiety, p = 0.01, p = 0.01

    Not recorded as a finding: Within-group change only, and no node for Beck anxiety inventory.

    In addition, within-group comparisons showed crocin significantly decreased anxiety (p-value= 0.01).

    PMID 38306888 · one of two readings recorded this

  • hs-CRP

    decreases, p = 0.01

    supplementation with crocin for 8 weeks significantly lowered hs-CRP levels (p-value= 0.01)

    PMID 38306888 · one of two readings recorded this

  • serum malondialdehyde (MDA), 8 weeks

    no effect

    Not recorded as a finding: Sentence 'did not affect serum MDA and NO' does not say whether it is a between-arm or within-arm test and gives no estimate.

    However, crocin did not affect serum MDA and NO after 8 weeks of intervention.

    PMID 38306888 · one of two readings recorded this

  • serum malondialdehyde

    no effect, did not affect serum MDA and NO after 8 weeks

    Not recorded as a finding: Assay (TBARS or HPLC) not stated and no estimate; the node requires the assay recorded with each finding. Sentence also pools MDA with NO.

    However, crocin did not affect serum MDA and NO after 8 weeks of intervention.

    PMID 38306888 · one of two readings recorded this

  • Serum MDA

    no effect

    crocin did not affect serum MDA and NO after 8 weeks of intervention

    PMID 38306888 · one of two readings recorded this

  • serum nitric oxide

    no effect, did not affect serum MDA and NO after 8 weeks

    Not recorded as a finding: No node for serum nitric oxide.

    However, crocin did not affect serum MDA and NO after 8 weeks of intervention.

    PMID 38306888 · one of two readings recorded this

  • Serum NO

    no effect

    crocin did not affect serum MDA and NO after 8 weeks of intervention

    PMID 38306888 · one of two readings recorded this

  • C-reactive protein (CRP)

    decreases, p = 0.008

    crocin supplementation significantly reduced c-reactive protein (CRP) levels (SMD: -0.50; 95%CI: -0.86 to -0.13; p = 0.008)

    PMID 39632602 · one of two readings recorded this

  • erythrocyte sedimentation rate (ESR), pooled meta-analysis

    no effect

    Not recorded as a finding: Node requires the Westergren method; abstract does not state the method.

    Overall effect size showed that crocin intake failed to change the erythrocyte sedimentation rate (ESR) and malondialdehyde (MDA) levels significantly.

    PMID 39632602 · one of two readings recorded this

  • Erythrocyte sedimentation rate (ESR)

    no effect

    Overall effect size showed that crocin intake failed to change the erythrocyte sedimentation rate (ESR) and malondialdehyde (MDA) levels significantly

    PMID 39632602 · one of two readings recorded this

  • Inflammatory markers

    decreases

    The effect of crocin on inflammatory markers was greater in a dose ≥ 30 mg/day and an intervention duration ≥ 12 weeks

    PMID 39632602 · one of two readings recorded this

  • Interleukin-6 (IL-6)

    decreases, p = 0.03

    interleukin-6 (IL-6) (SMD: -3.52; 95%CI: -6.84 to -0.20; p = 0.03)

    PMID 39632602 · one of two readings recorded this

  • Malondialdehyde (MDA)

    no effect

    Overall effect size showed that crocin intake failed to change the erythrocyte sedimentation rate (ESR) and malondialdehyde (MDA) levels significantly

    PMID 39632602 · one of two readings recorded this

  • Total antioxidant capacity (TAC)

    increases, p = 0.002

    crocin supplementation led to a significant increase in total antioxidant capacity (TAC) (SMD: 1.48; 95%CI: 0.52 to 2.43; p = 0.002)

    PMID 39632602 · one of two readings recorded this

  • Tumor necrosis factor-α (TNF-α)

    decreases, p = 0.001

    tumor necrosis factor-α (TNF-α) (SMD: -1.96; 95%CI: -2.72 to -1.19; p < 0.001)

    PMID 39632602 · one of two readings recorded this

  • Change in heart rate from baseline

    decreases, p = 0.008

    The changes in heart rate from baseline to 6 months showed a significant difference as the mean difference of -4.00 (95 %CI, -6.95 to -1.05) bpm (P = 0.008)

    PMID 39889867 · one of two readings recorded this

  • Mean change in NT-proBNP

    unclear, p = 0.017

    At 6 months, there were significant differences in the mean change of N-terminal pro-brain natriuretic peptide (NT-pro BNP) between the groups (3.06 [-25.18-6.95] vs. 3.06 [-4.85-24.98] pg/ml; P = 0.017)

    PMID 39889867 · one of two readings recorded this

  • proportion of patients with a drop in left ventricular ejection fraction (LVEF) of at least 10 % from baseline until 6 months, anthracycline-induced cardiotoxicity

    7.2 % (7/97) in the crocin group versus 17.7 % (17/96) in the placebo group, p = 0.027

    Not recorded as a finding: this platform holds no node for the endpoint

    The incidence of the primary efficacy outcome was 7.2 % (7/97) in the crocin group and 17.7 % (17/96) in the placebo group (P = 0.027).

    PMID 39889867 · one of two readings recorded this

  • proportion of patients with a drop in left ventricular ejection fraction of at least 10% from baseline to 6 months, crocin tablets versus placebo during anthracycline chemotherapy

    7.2% (7/97) crocin versus 17.7% (17/96) placebo, p = 0.027

    Not recorded as a finding: this platform holds no node for the endpoint

    The incidence of the primary efficacy outcome was 7.2 % (7/97) in the crocin group and 17.7 % (17/96) in the placebo group (P = 0.027).

    PMID 39889867 · one of two readings recorded this

  • Proportion with LVEF drop of at least 10 % from baseline

    decreases, p = 0.027, n = 193

    The incidence of the primary efficacy outcome was 7.2 % (7/97) in the crocin group and 17.7 % (17/96) in the placebo group (P = 0.027)

    PMID 39889867 · one of two readings recorded this

  • Lipid profile and fasting blood glucose (FBG)

    no effect, n = 28

    no significant difference was detected among the other biochemical factors (lipid profile and FBG) between two groups

    PMID 40817397 · one of two readings recorded this

  • serum IL-2, IL-10, VEGF and INF γ, sandwich chemiluminescence assay, in metabolic syndrome

    decreases, significantly reduced after Crocin treatment, P < 0.05

    Not recorded as a finding: this platform holds no node for the endpoint

    Our results indicated that inflammatory factors including IL-2, IL-10, VEGF and INF γ, were significantly reduced (P < 0.05) in patients with Mets after Crocin treatment.

    PMID 40817397 · one of two readings recorded this

  • serum IL-2, IL-10, VEGF and interferon-gamma, sandwich chemiluminescence assay, before and after 8 weeks of crocin 15 mg versus placebo in metabolic syndrome

    decreases, significantly reduced (P < 0.05) after Crocin treatment

    Not recorded as a finding: this platform holds no node for the endpoint

    Our results indicated that inflammatory factors including IL-2, IL-10, VEGF and INF γ, were significantly reduced (P < 0.05) in patients with Mets after Crocin treatment.

    PMID 40817397 · one of two readings recorded this

  • Serum inflammatory cytokines (IL-2, IL-10, VEGF, INF γ)

    decreases, p = 0.05, n = 28

    inflammatory factors including IL-2, IL-10, VEGF and INF γ, were significantly reduced (P < 0.05) in patients with Mets after Crocin treatment

    PMID 40817397 · one of two readings recorded this